SCHEMBL5714828

SCHEMBL5714828

O=C(O)Cc1ccc(N2CCN(C(=O)Oc3ccc(CCOc4ccncc4)cc3)CC2)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ME2 P23368 7/20 0.47
ME1 P48163 7/20 0.47
ME3 Q16798 7/20 0.47
PANK3 Q9H999 1/20 0.46
SLC6A7 Q99884 1/20 0.44
AOC3 Q16853 1/20 0.41
CYP4F2 P78329 1/20 0.40
CYP4A11 Q02928 1/20 0.40
ALDH1A1 P00352 2/20 0.39
TSHR P16473 2/20 0.39
MAPK1 P28482 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HSD17B10 Q99714 2/20 0.39
TRPA1 O75762 2/20 0.39
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2C9 P11712 2/20 0.39
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714805 0.90 SLC6A7 (0.44) ME2ME1ME3PANK3SLC6A7
SCHEMBL5715214 0.89 SLC6A7 (0.48) ME2ME1ME3PANK3SLC6A7
SCHEMBL5714635 0.88 PANK3 (0.42) ME2ME1ME3PANK3AOC3
SCHEMBL5714406 0.87 ME2 (0.50) ME2ME1ME3PANK3SLC6A7
SCHEMBL5714506 0.87 TRPA1 (0.49) ME2ME1ME3PANK3SLC6A7
SCHEMBL5714477 0.87 ME2 (0.50) ME2ME1ME3PANK3SLC6A7
SCHEMBL5714629 0.86 HSD17B10 (0.46) ME2ME1ME3PANK3SLC6A7
SCHEMBL5714123 0.85 SMN1; SMN2 (0.57) ME2ME1ME3ALDH1A1SMN1; SMN2
SCHEMBL5714610 0.84 HSD17B10 (0.54) SLC6A7ALDH1A1TSHRMAPK1SMN1; SMN2
SCHEMBL5715126 0.83 KDM4E (0.50) ME2ME1ME3PANK3SLC6A7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC ME2 854/4885ME1 2914/4885ME3 1308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.